Boundless Bio Inc (BOLD)
Boundless Bio, Inc. is a clinical-stage oncology company focused on developing therapies that target extrachromosomal DNA, or ecDNA, for patients with oncogene-amplified cancers. Its lead candidate, BBI-940, is an ecDNA-directed therapeutic being evaluated in a Phase 1/2 trial in patients with estrogen receptor positive, HER2-negative breast cancer, as well as triple-negative breast cancer with a luminal androgen receptor subtype. The company was incorporated in 2018, changed its name from Pretzel Therapeutics, Inc. in July 2019, and is headquartered in San Diego, California. Boundless Bio’s common stock trades on the NASDAQ under the symbol BOLD.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BOLD
|
$2.97
|
19.1% Upside
|
Undervalued
|
$4
|
60.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-1.0x
|
0.7x
|
—
|
54.809 M
|
11.598 M
|
46.8%
|
73.1%
|
-2.8
|
—
|
85.0%
|
